Trulieve Added to S&P Total Market and Completion Indices

Index Inclusion Expands Institutional Visibility

Trulieve's addition to the S&P Total Market Index positions the company within a benchmark tracking roughly 3,500 U.S. equities across all market capitalizations. The TMI represents the investable opportunity set for U.S. equity managers, with constituents weighted by float-adjusted market cap. The Completion Index covers mid- and small-cap segments excluded from the S&P 500.

Index inclusion typically triggers passive inflows from funds tracking those benchmarks. S&P doesn't disclose weighting methodologies for individual constituents ahead of rebalancing, but Trulieve's float-adjusted market cap of roughly $1.2 billion as of September 20 suggests modest initial weighting.

Why This Matters for Cannabis Equities

No U.S. MSO has previously qualified for S&P's broad-market indices due to federal illegality and exchange-listing constraints. Trulieve trades on the Canadian Securities Exchange under ticker TRUL and on U.S. over-the-counter markets as TCNNF. S&P's index methodology historically excluded OTC-listed securities, but recent updates allow inclusion of foreign-listed companies meeting liquidity and governance thresholds.

The move signals institutional index providers are treating cannabis operators as investable equities despite Schedule I classification. That's a break from 2018-2022, when most index funds excluded cannabis entirely.

Trulieve's Operational Footprint

Trulieve operates 195 retail dispensaries across 11 states. Florida accounts for 126 locations—the company's core market. Q2 2026 revenue hit $295 million, up 8% year-over-year, driven by Florida adult-use sales following the state's April 2026 legalization. Adjusted EBITDA for the quarter was $89 million, a 30% margin.

The company's vertically integrated model—cultivation, processing, and retail under one license—has delivered consistent profitability in a sector where most MSOs remain cash-flow negative. Positive adjusted EBITDA for 18 consecutive quarters.

S&P Health Care Sub-Index Context

Inclusion in the TMI Health Care and CI Health Care sub-indices places Trulieve alongside pharmaceutical manufacturers, biotech firms, and medical device companies. S&P classifies cannabis operators under GICS code 35102010 (Pharmaceuticals), a designation that's drawn criticism from industry analysts who argue cannabis retail resembles consumer staples more than drug development.

Health care classification may attract sector-specific ETFs and mutual funds with mandates to track health care indices. It also positions Trulieve for potential inclusion in broader health care benchmarks if S&P expands its cannabis coverage.

Institutional Ownership and Passive Flows

Trulieve's institutional ownership stood at 11% as of August 2026. That's below the 40-60% range typical for mid-cap U.S. equities. Index inclusion should lift that figure as passive funds rebalance portfolios to match TMI and CI weightings. Vanguard, BlackRock, and State Street—the three largest index fund managers—collectively oversee $4.2 trillion in TMI-tracking assets.

Passive inflows won't be immediate or dramatic. Most index funds rebalance quarterly, and Trulieve's weighting will be fractional. Still, the precedent matters: if S&P adds one MSO, others meeting liquidity and governance criteria may follow.

The institutional capital question for U.S. cannabis has never been about risk appetite—it's been about index eligibility and compliance infrastructure. Trulieve just cleared the first gate.

Federal Rescheduling and Index Methodology

The DEA's proposed rescheduling of cannabis to Schedule III, currently under OMB review, could accelerate index inclusion for other MSOs. Schedule III status wouldn't resolve federal illegality, but it would eliminate the Section 280E tax burden and potentially ease exchange-listing barriers. Nasdaq and NYSE both prohibit listings of companies violating federal law, a policy that's confined U.S. cannabis operators to Canadian exchanges and OTC markets.

S&P's decision to include Trulieve under current law suggests index providers are moving ahead of regulatory clarity. That's a shift from 2021, when MSCI and FTSE Russell explicitly excluded U.S. cannabis from their indices citing federal prohibition.

What to Watch Next

The next signal: whether other MSOs with similar market caps and liquidity profiles—Curaleaf, Green Thumb Industries, Verano—gain index inclusion in Q4 2026 rebalancing cycles. S&P's index committee meets quarterly to review eligibility. Trulieve's inclusion sets the precedent, but it doesn't guarantee a sector-wide wave.

For full background on Trulieve's expansion strategy and financial performance, see the CannIntel topic hub on Trulieve Cannabis.